ALK+ ADVANCED NSCLC

Clinical trials for ALK+ ADVANCED NSCLC explained in plain language.

Never miss a new study

Get alerted when new ALK+ ADVANCED NSCLC trials appear

Sign up with your email to follow new studies for ALK+ ADVANCED NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Head-to-Head showdown: which drug works better against tough lung cancer?

Disease control Completed

This study compared two oral medications, brigatinib and alectinib, for people with advanced ALK-positive lung cancer whose cancer had worsened while taking their first targeted therapy. The trial involved 248 participants worldwide who were randomly assigned to receive one of th…

Matched conditions: ALK+ ADVANCED NSCLC

Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control

Last updated Mar 23, 2026 15:29 UTC

ALK+ ADVANCED NSCLC

Get alerted when new ALK+ ADVANCED NSCLC trials appear

Head-to-Head showdown: which drug works better against tough lung cancer?